We’re proud to share that we filed a CTA to launch a clinical trial for NTLA-2002, an in vivo #CRISPR candidate targeting the root cause #HereditaryAmgiodema (HAE), a rare, life-threatening disorder. #NewEraofMedicine. https://t.co/7K2kwqEOy4